Vernon Michael Holers
Physician at Hudson, Denver, CO
License number
Colorado 23841
Issued Date
Jun 11, 1981
Renew Date
May 1, 2015
Expiration Date
Apr 30, 2017
Type
Physician
Address
Address
242 S Hudson St S HUDSON, Denver, CO 80246
Personal information
See more information about Vernon Michael Holers at radaris.comName
Address
Phone
4825 E 1St Ave, Denver, CO 80220
2425 Hudson St, Denver, CO 80207
242 Hudson St, Denver, CO 80246
Professional information
Vernon Holers, Aurora CO
Work:
Rheumatology
1775 Aurora Ct, Aurora, CO 80045
1775 Aurora Ct, Aurora, CO 80045
Vernon Michael Holers, Aurora CO
Specialties:
Rheumatologist
Address:
12605 E 16Th Ave, Aurora, CO 80045
Inhibition Of Factor B And The Alternative Complement Pathway For Treatment Of Traumatic Brain Injury And Related Conditions
US Patent:
2006029, Dec 28, 2006
Filed:
May 26, 2006
Appl. No.:
11/441828
Inventors:
Vernon Holers - Denver CO, US
Joshua Thurman - Greenwood Village CO, US
Stephen Tomlinson - Mount Pleasant SC, US
Philip Stahel - Denver CO, US
Joshua Thurman - Greenwood Village CO, US
Stephen Tomlinson - Mount Pleasant SC, US
Philip Stahel - Denver CO, US
Assignee:
The Regents of the University of Colorado - Boulder CO
MUSC Foundation for Research Development - Charleston SC
MUSC Foundation for Research Development - Charleston SC
International Classification:
A61K 39/395
US Classification:
424144100
Abstract:
Disclosed is the use of agents and compositions that selectively inhibit the alternative complement pathway for the inhibiting or treating physiological damage resulting from traumatic brain injury (TBI), spinal cord injury (SCI), or related conditions. Preferred reagents for use in inhibition of damage resulting from TBI or SCI include those that inhibit factor B, with anti-factor B antibodies representing a particularly preferred agent.
Prevention And Treatment Of Ischemia-Reperfusion Injury And Related Conditions
US Patent:
2013017, Jul 4, 2013
Filed:
Aug 21, 2012
Appl. No.:
13/591181
Inventors:
Vernon Michael Holers - Denver CO, US
Liudmila Kulik - Aurora CO, US
George C. Tsokos - Silver Springs MD, US
Stephen Tomlinson - Mount Pleasant SC, US
Liudmila Kulik - Aurora CO, US
George C. Tsokos - Silver Springs MD, US
Stephen Tomlinson - Mount Pleasant SC, US
Assignee:
MEDICAL UNIVERSITY OF SOUTH CAROLINA - Charleston SC
THE REGENTS OF THE UNIVERSITY OF COLORADO, a body corporate - Denver CO
THE REGENTS OF THE UNIVERSITY OF COLORADO, a body corporate - Denver CO
International Classification:
A61K 38/17, A61K 31/685, A61K 9/127
US Classification:
424450, 514 151, 514 78
Abstract:
Disclosed are lipids, annexin, and lipid-annexin complexes for use in the prevention and/or treatment of ischemia-reperfusion injury and reperfusion injury associated with a variety of diseases and conditions. Also disclosed are therapeutic targets and compositions for the prevention and treatment of ischemia-reperfusion injury and diseases and conditions associated with ischemia-reperfusion injury.
Anti-Factor B Antibodies
US Patent:
7999082, Aug 16, 2011
Filed:
Feb 10, 2005
Appl. No.:
11/057047
Inventors:
Vernon Michael Holers - Denver CO, US
Joshua M. Thurman - Greenwood Village CO, US
Christian Taube - Denver CO, US
Erwin W. Gelfand - Englewood CO, US
Gary Steven Gilkeson - Charleston SC, US
Joshua M. Thurman - Greenwood Village CO, US
Christian Taube - Denver CO, US
Erwin W. Gelfand - Englewood CO, US
Gary Steven Gilkeson - Charleston SC, US
Assignee:
National Jewish Medical and Research Center - Denver CO
MUSC Foundation for Research Development - Charleston SC
The Regents of the University of Coloraodo - Boulder CO
MUSC Foundation for Research Development - Charleston SC
The Regents of the University of Coloraodo - Boulder CO
International Classification:
C07K 16/36, C07K 16/00, A61K 39/395
US Classification:
53038825, 5303871, 5303873, 5303881, 5303882, 4241301, 4241331, 4241411, 4241451, 4241581
Abstract:
Disclosed are novel inhibitors of the alternative complement pathway and particularly, novel anti-factor B antibodies. Also disclosed is the use of such inhibitors to reduce or prevent airway hyperresponsiveness and/or airway inflammation by selectively inhibiting the alternative complement pathway, thereby treating diseases in which such conditions play a role. Also disclosed is the use of such inhibitors to reduce or prevent other diseases and conditions, including ischemia-reperfusion injury, by inhibition of the alternative complement pathway.
Three-Dimensional Structure Of Complement Receptor Type 2 And Uses Thereof
US Patent:
8465737, Jun 18, 2013
Filed:
Apr 12, 2007
Appl. No.:
11/786788
Inventors:
Xiaojiang Chen - Denver CO, US
Vernon Michael Holers - Denver CO, US
Vernon Michael Holers - Denver CO, US
Assignee:
The Regents of the University of Colorado - Denver CO
International Classification:
C07K 16/00, C07K 16/28, C07K 16/46, C07K 16/18, A61K 39/395
US Classification:
4241301, 4241331, 4241411, 4241431, 5303871, 5303873, 5303881, 53038822, 435 7021
Abstract:
Disclosed is a crystalline human CR2 protein in complex with C3d, and the three dimensional structure of the crystalline complex. Also disclosed are methods of use of the structure, particularly for structure-based identification of compounds that bind to CR2 and inhibit or enhance the binding of CR2 to a natural ligand, that bind to CR2 and agonize or antagonize the receptor, that bind to CR2 and inhibit or enhance CR2 dimerization, or that use the C3-binding ability of CR2 as a drug delivery vehicle. Also disclosed are therapeutic compounds obtained by such methods and uses for such compounds.
Three-Dimensional Structure Of Complement Receptor Type 2 And Uses Thereof
US Patent:
2004000, Jan 8, 2004
Filed:
Apr 11, 2001
Appl. No.:
09/834309
Inventors:
Xiaojiang Chen - Denver CO, US
Vernon Holers - Denver CO, US
Vernon Holers - Denver CO, US
International Classification:
C12Q001/70, A61K031/00, G06F019/00, G01N033/48, G01N033/50
US Classification:
435/005000, 514/001000, 702/019000
Abstract:
Disclosed is a crystalline human CR2 protein in complex with C3d, and the three dimensional structure of the crystalline complex. Also disclosed are methods of use of the structure, particularly for structure-based identification of compounds that bind to CR2 and inhibit or enhance the binding of CR2 to a natural ligand, that bind to CR2 and agonize or antagonize the receptor, that bind to CR2 and inhibit or enhance CR2 dimerization, or that use the C3-binding ability of CR2 as a drug delivery vehicle. Also disclosed are therapeutic compounds obtained by such methods and uses for such compounds.
Three-Dimensional Structure Of Complement Receptor Type 2 And Uses Thereof
US Patent:
2006001, Jan 19, 2006
Filed:
Aug 16, 2004
Appl. No.:
10/921415
Inventors:
Xiaojiang Chen - Denver CO, US
Vernon Holers - Denver CO, US
Vernon Holers - Denver CO, US
International Classification:
A61K 38/17, A61K 9/14
US Classification:
514012000, 424488000
Abstract:
Disclosed is a crystalline human CR2 protein in complex with C3d, and the three dimensional structure of the crystalline complex. Also disclosed are methods of use of the structure, particularly for structure-based identification of compounds that bind to CR2 and inhibit or enhance the binding of CR2 to a natural ligand, that bind to CR2 and agonize or antagonize the receptor, that bind to CR2 and inhibit or enhance CR2 dimerization, or that use the C3-binding ability of CR2 as a drug delivery vehicle. Also disclosed are therapeutic compounds obtained by such methods and uses for such compounds.
Inhibition Of Factor B, The Alternative Complement Pathway And Methods Related Thereto
US Patent:
2008007, Mar 27, 2008
Filed:
Aug 3, 2007
Appl. No.:
11/888997
Inventors:
Vernon Holers - Denver CO, US
Joshua Thurman - Greenwood Village CO, US
Christian Taube - Denver CO, US
Erwin Gelfand - Englewood CO, US
Gary Gilkeson - Charleston SC, US
Joshua Thurman - Greenwood Village CO, US
Christian Taube - Denver CO, US
Erwin Gelfand - Englewood CO, US
Gary Gilkeson - Charleston SC, US
International Classification:
C07K 16/46, A61K 39/395, A61P 11/06
US Classification:
424134100, 530391100
Abstract:
Disclosed are novel inhibitors of the alternative complement pathway and particularly, novel anti-factor B antibodies. Also disclosed is the use of such inhibitors to reduce or prevent airway hyperresponsiveness and/or airway inflammation by selectively inhibiting the alternative complement pathway, thereby treating diseases in which such conditions play a role. Also disclosed is the use of such inhibitors to reduce or prevent other diseases and conditions, including ischemia-reperfusion injury, by inhibition of the alternative complement pathway.
Prevention And Treatment Of Ischemia-Reperfusion Injury And Related Conditions
US Patent:
2011001, Jan 20, 2011
Filed:
Mar 27, 2007
Appl. No.:
12/294870
Inventors:
Vernon Michael Holers - Denver CO, US
Liudmila Kulik - Aurora CO, US
George C. Tsokos - Silver Springs MD, US
Stephen Tomlinson - Mount Pleasant SC, US
Liudmila Kulik - Aurora CO, US
George C. Tsokos - Silver Springs MD, US
Stephen Tomlinson - Mount Pleasant SC, US
Assignee:
THE REGENTS OF THE UNIVERSITY OF COLORADO - Denver CO
International Classification:
A61K 9/127, A61K 38/16, A61K 39/395, C07K 16/00, C07K 14/00, A61P 9/10, A61P 13/12, A61P 25/00, A61P 37/06
US Classification:
424450, 514 151, 4241721, 5303891, 530402
Abstract:
Disclosed are Lipids, Annexin, and Lipid-Annexin Complexes for Use in the Prevention and/or Treatment of Ischemia-Reperfusion injury and reperfusion injury associated with a variety of diseases and conditions. Also disclosed are therapeutic targets and compositions for the prevention and treatment of ischemia-reperfusion injury and diseases and conditions associated with ischemia-reperfusion injury.